Cowen and Company reissued their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research report sent to investors on Thursday morning. The firm currently has a $69.00 price target on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Piper Jaffray Companies set a $43.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a research note on Thursday, May 18th. Nomura reissued a buy rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. Oppenheimer Holdings, Inc. reissued a buy rating and set a $76.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Needham & Company LLC reissued a buy rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. Finally, Royal Bank Of Canada reissued a buy rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $62.31.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 46.51 on Thursday. The company’s 50 day moving average price is $39.72 and its 200 day moving average price is $34.68. The stock’s market capitalization is $2.99 billion. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. Sarepta Therapeutics’s quarterly revenue was up 350000.0% on a year-over-year basis. During the same period last year, the firm earned ($1.19) EPS. On average, analysts expect that Sarepta Therapeutics will post ($1.23) earnings per share for the current fiscal year.

WARNING: “Sarepta Therapeutics’ (SRPT) “Outperform” Rating Reiterated at Cowen and Company” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/18/sarepta-therapeutics-srpt-outperform-rating-reiterated-at-cowen-and-company.html.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 47,058 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was purchased at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the completion of the purchase, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alexander Cumbo sold 5,918 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the transaction, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at approximately $934,513. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 in the last ninety days. Insiders own 9.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in SRPT. Russell Investments Group Ltd. raised its stake in Sarepta Therapeutics by 63.9% during the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 14,919 shares during the last quarter. Wells Fargo & Company MN raised its stake in Sarepta Therapeutics by 24.4% during the first quarter. Wells Fargo & Company MN now owns 84,710 shares of the biotechnology company’s stock worth $2,508,000 after buying an additional 16,620 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Sarepta Therapeutics by 0.8% during the first quarter. Bank of New York Mellon Corp now owns 247,924 shares of the biotechnology company’s stock worth $7,339,000 after buying an additional 1,923 shares during the last quarter. Pictet Asset Management Ltd. raised its stake in Sarepta Therapeutics by 24.7% during the first quarter. Pictet Asset Management Ltd. now owns 67,600 shares of the biotechnology company’s stock worth $2,001,000 after buying an additional 13,400 shares during the last quarter. Finally, Swiss National Bank raised its stake in Sarepta Therapeutics by 3.9% during the first quarter. Swiss National Bank now owns 85,400 shares of the biotechnology company’s stock worth $2,528,000 after buying an additional 3,200 shares during the last quarter. 65.41% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.